New targets and treatments in multiple myeloma: Src family kinases as central regulators of disease progression

Position statement on the use of bortezomib in multiple myeloma

(2010) G. J. MORGAN et al.   International Journal of Laboratory Hematology

Validation of PDGFR  and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib

(2008) A. M. L. Coluccia et al.   BLOOD

Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL™), a multi-targeted kinase inhibitor

(2008) Feng (Roger) Luo et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity

(2008) J. C. Montero et al.   HAEMATOLOGICA

High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma

(2008) J. El-Cheikh et al.   HAEMATOLOGICA

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression

(2008) M.-V. Mateos et al.   HAEMATOLOGICA

Small-molecule inhibition of proteasome and silencing by vascular endothelial cell growth factor-specific siRNA induce additive antitumor activity in multiple myeloma

(2008) Michael Koldehoff et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE